GILEAD SCIENCES, INC. Financial and Nonfinancial Liabilities, Fair Value Disclosure
GILEAD SCIENCES, INC. (GILD) had Financial and Nonfinancial Liabilities, Fair Value Disclosure of $535.00 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Fair Value, Net Asset (Liability)
us-gaap:LiabilitiesFairValueDisclosure · last filed 2026-08-06
- 2026-06-30: Financial and Nonfinancial Liabilities, Fair Value Disclosure $535.00M.
- 2025-12-31: Financial and Nonfinancial Liabilities, Fair Value Disclosure $757.00M.
- 2013-06-30: Financial and Nonfinancial Liabilities, Fair Value Disclosure $236.38M.
- 2013-03-31: Financial and Nonfinancial Liabilities, Fair Value Disclosure $229.75M.
| Period end | Financial and Nonfinancial Liabilities, Fair Value Disclosure |
|---|---|
| 2026-06-30 | $535.00M 10-Q · filed 2026-08-06 |
| 2025-12-31 | $757.00M 10-Q · filed 2026-08-06 |
| 2013-06-30 | $236.38M 10-Q · filed 2013-08-01 |
| 2013-03-31 | $229.75M 10-Q · filed 2013-05-08 |
| 2012-12-31 | $270.31M 10-Q · filed 2013-08-01 |
| 2012-09-30 | $233.84M 10-Q · filed 2012-11-06 |
| 2012-06-30 | $144.99M 10-Q · filed 2012-08-01 |
| 2012-03-31 | $156.73M 10-Q · filed 2012-05-04 |
| 2011-12-31 | $141.30M 10-K · filed 2013-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |